Related Experiment Video
Updated: Jun 6, 2026

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic
Oren Gilad1, Barzin Y Nabet, Ryan L Ragland
1Abramson Family Cancer Research Institute and Department of Cancer Biology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Abstract:
Previous studies indicate that oncogenic stress activates the ATR-Chk1 pathway. Here, we show that ATR-Chk1 pathway engagement is essential for limiting genomic instability following oncogenic Ras transformation. ATR pathway inhibition in combination with oncogenic Ras expression synergistically increased genomic instability, as quantified by chromatid breaks, sister chromatid exchanges, and H2AX phosphorylation. This level of instability was significantly greater than that observed following ATR suppression in untransformed control cells. In addition, consistent with a deficiency in long-term genome maintenance, hypomorphic ATR pathway reduction to 16% of normal levels was synthetic lethal with oncogenic Ras expression in cultured cells. Notably, elevated genomic instability and synthetic lethality following suppression of ATR were not due to accelerated cycling rates in Ras-transformed cells, indicating that these synergistic effects were generated on a per-cell-cycle basis. In contrast to the synthetic lethal effects of hypomorphic ATR suppression, subtle reduction of ATR expression (haploinsufficiency) in combination with endogenous levels of K-ras(G12D) expression elevated the incidence of lung adenocarcinoma, spindle cell sarcoma, and thymic lymphoma in p53 heterozygous mice. K-ras(G12D)-induced tumorigenesis in ATR(+/-)p53(+/-) mice was associated with intrachromosomal deletions and loss of wild-type p53. These findings indicate that synergistic increases in genomic instability following ATR reduction in oncogenic Ras-transformed cells can produce 2 distinct biological outcomes: synthetic lethality upon significant suppression of ATR expression and tumor promotion in the context of ATR haploinsufficiency. These results highlight the importance of the ATR pathway both as a barrier to malignant progression and as a potential target for cancer treatment.
Insights
The ATR-Chk1 pathway limits genomic instability from oncogenic Ras. Suppressing ATR causes synthetic lethality or promotes tumors, highlighting ATR as a cancer target.
Area of Science:
- Genetics
- Molecular Biology
- Cancer Research
Background:
- Oncogenic stress activates the ATR-Chk1 pathway.
- The ATR-Chk1 pathway's role in limiting genomic instability during oncogenic transformation is crucial.
Purpose of the Study:
- To investigate the role of the ATR-Chk1 pathway in maintaining genomic stability under oncogenic Ras transformation.
- To explore the consequences of ATR pathway inhibition or reduction in the context of oncogenic Ras.
Main Methods:
- Quantification of genomic instability (chromatid breaks, sister chromatid exchanges, H2AX phosphorylation).
- Assessment of synthetic lethality upon hypomorphic ATR reduction with oncogenic Ras.
- Evaluation of tumor promotion in p53 heterozygous mice with ATR haploinsufficiency and K-ras(G12D) expression.
Main Results:
- ATR pathway inhibition synergistically increased genomic instability with oncogenic Ras.
- Hypomorphic ATR reduction was synthetic lethal with oncogenic Ras, independent of cell cycling.
- ATR haploinsufficiency with K-ras(G12D) promoted lung adenocarcinoma, sarcoma, and lymphoma in mice, associated with deletions and p53 loss.
Conclusions:
- ATR pathway reduction leads to distinct outcomes: synthetic lethality or tumor promotion, depending on the degree of suppression.
- The ATR pathway is a critical barrier against malignant progression.
- ATR pathway modulation presents a potential therapeutic strategy for cancers driven by oncogenic Ras.
More Related Videos
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Related Concept Videos
The Ras Gene
Ras is a superfamily...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Mutagenicity and Carcinogenicity